HOUSTON, Sept. 9, 2026 /PRNewswire/ -- ImmunoGenesis, a clinical-stage biotech company developing innovative, science-driven immunotherapies, announces the appointment of Reza Mazhari, Ph.D., and Mike Davis to its Board of Directors. Dr. Reza Mazhari has more than 25 years of life science operating experience in drug discovery, early-stage clinical development and…
Read More
lmmuno-oncology leader brings more than three decades of experience advancing innovative cancer therapies across biotech, pharma, and the National Cancer Institute HOUSTON, May 28, 2026 /PRNewswire/ -- lmmunoGenesis, a clinical-stage biotech company developing innovative, science-driven immunotherapies, today announced the appointment of Claudio Dansky Ullmann, M.D. as Chief Medical Officer. Dr…
Read More
Presentation details the IND-enabling work for IMGS-203, a potent Stimulator of Interferon Genes (STING) Agonist, for the treatment of Glioblastoma Multiforme (GBM) Houston, Texas, April 15, 2026 /PR Newswire/— ImmunoGenesis, a clinical-stage biotech company developing innovative, science-driven immunotherapies, today announced that it will present a poster at the upcoming American…
Read More
Leveraging AI-Driven Multiomics and Spatial Biology to Unlock the Full Potential of Next-Generation Cytotoxic Dual Checkpoint Inhibitor WALTHAM, Mass. & HOUSTON--(BUSINESS WIRE)--BostonGene, developer of the leading AI foundation model for tumor and immune biology, and ImmunoGenesis, a clinical-stage biotech company developing innovative, science-driven immunotherapies, today announced a strategic partnership to accelerate…
Read More
IMGS-001 is a cytotoxic immune checkpoint inhibitor targeting PD-L1 and PD-L2 and is designed to treat the many “immune-excluded” cancers that are resistant to existing immunotherapies Houston, Texas, Dec. 4, 2025 /PR Newswire/— ImmunoGenesis, a clinical-stage biotech company developing innovative, science-driven immunotherapies, announced today that the company has been awarded…
Read More
ImmunoGenesis Announces the Formation of Scientific Advisory Board Initial meeting of Scientific Advisory Board (SAB) convened to discuss the first-in-human phase 1a/1b clinical trial of IMGS-001, a dual-specific PD-L1/PD-L2 antibody with cytotoxic killing function designed to treat the many “immune-excluded” cancers that are resistant to existing immunotherapies HOUSTON, July 01,…
Read More
Source: Cancer Focus Fund ImmunoGenesis Expands Phase 1a/b Trial of IMGS-001 for Advanced Solid Tumors to Ochsner MD Anderson Cancer Center First dual-specific PD-L1/PD-L2 antibody with cytotoxic killing function is designed to treat the many “immune-excluded” cancers that are resistant to existing immunotherapies Promising early signals of activity seen as…
Read More
ImmunoGenesis Doses First Patient in Phase 1/2 Clinical Trial of IMGS-101 in Combination With Balstilimab (anti-PD-1) and Zalifrelimab (anti-CTLA-4) in Relapsed or Refractory Advanced Prostate, Pancreatic, and HPV(-) Head & Neck Tumors IMGS-101 is the only known reducer of solid tumor hypoxia, offering the potential to enhance the efficacy of…
Read More
PolyPid Announces Research and Development Collaboration with ImmunoGenesis Leveraging PLEX Technology to Enhance Cancer Immunotherapy PETACH TIKVA, Israel, Dec. 11, 2024 (GLOBE NEWSWIRE) --PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced a new research and development collaboration with…
Read More
ImmunoGenesis Doses First Patient in Phase 1a/1b Clinical Trial of IMGS-001 in Relapsed or Refractory Advanced Solid Tumors IMGS-001 is the first dual-specific PD-L1/PD-L2 antibody with cytotoxic function designed to treat immune-excluded cancers that are resistant to existing immunotherapies See more here
Read More